Vigamox Treatment for Ocular Graft-Versus-Host Disease

Ocular Graft-versus-host Disease Clinical Trial

Official title:
Evaluation of Topical Vigamox in the Initial Management of Ocular Graft-Versus-Host Disease

Status Withdrawn

Clinical Trial Summary

In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The investigators will accomplish this by enrolling patients with bilateral ocular GVHD and treating one eye with topical Vigamox and the other eye with a placebo eye drop. By assessing the response to treatment with Vigamox, the investigators hope to identify a role for topical antibiotic treatment in ocular GVHD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04204122
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Withdrawn
Phase	Phase 2
Start date	June 15, 2020
Completion date	March 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04792580` - The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease	Early Phase 1
Recruiting	`NCT06348602` - Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT	Phase 1/Phase 2
Active, not recruiting	`NCT04769648` - Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease	Phase 2/Phase 3
Recruiting	`NCT05311514` - Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease	Phase 2